Dysregulation of small nucleolar RNA host gene 6 (SNHG6) exerts critical oncogenic effects and facilitates tumourigenesis in human cancers. However, little information
| INTRODUC TI ON
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy in the world, and its incidence has increased in the last decade. [1] [2] [3] Of the several subtypes of EOC, ovarian clear cell carcinoma (OCCC) represents 5%-25% of all EOCs depending on geographic location, and gene expression studies support the idea that OCCC is distinct from other EOCs, with a poorer prognosis due to a lower response rate to anticancer drug treatment. [3] [4] [5] Identifying novel therapeutic targets and establishing new treatment strategies for OCCC is thus important.
In recent years, long non-coding RNAs (lncRNAs) have been reported as a category of non-coding RNAs with a length of greater than 200 nucleotides that do not encode proteins, and the emerging impact of lncRNAs in cancer initiation and progression has been discovered in diverse types of cancer, including OCCC. [6] [7] [8] is a novel molecule involved in OCCC progression and that targeting the ceRNA network involving SNHG6 may be a treatment strategy in OCCC.
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evidence indicates that lncRNAs are involved in a variety of biological processes such as cell apoptosis, proliferation, metastasis, chemotherapeutic drug resistance and differentiation, suggesting that lncRNAs can be useful diagnostic markers or therapeutic agents for cancers. 6, 9 For example, overexpression of MALAT1 and PVT1
promotes cancer cell proliferation and survival in gastrointestinal tumours. [10] [11] [12] However, lncRNA-p21 was reported to be down-regulated and to suppress the growth and metastasis of cancer cells. 13, 14 Currently, some small nucleolar RNAs (snoRNAs), a subclass of lncRNAs, exhibit differential expression patterns in various human cancers and demonstrate the ability to affect cell transformation, tumourigenesis and metastasis. 15, 16 Small nucleolar RNA host gene 6 (SNHG6), also known as U87HG, is a recently identified lncRNA shown to be a potential oncogene involved in cell proliferation and epithelial-mesenchymal transition (EMT) progression in many cancers. [17] [18] [19] [20] [21] [22] However, the activities of SNHG6 related to OCCC tumourigenesis have not been well characterized, prompting us to explore the role of SNHG6 in human OCCC. In this study, we revealed that SNHG6 was overexpressed in OCCC tissues and that this lncRNA promoted cell proliferation, migration and invasion in vitro as well as tumour growth in vivo. Mechanistically, SNHG6 facilitated the development of OCCC by sponging miR-4465, which targets enhancer of zeste homolog 2 (EZH2). In summary, our study revealed the role of SNHG6 and first revealed that SNHG6 could sponge miR-4465 in OCCC.
| MATERIAL S AND ME THODS

| Human samples and tissue handling
This study was conducted with the understanding and written consent of each individual. The study methodologies conformed to the standards established by the Declaration of Helsinki. All human tissues were collected using the protocols approved by the Human Ethics Committee of the Fudan University Shanghai Cancer Center.
Ovarian clear cell carcinoma tissues were obtained from 48 patients who underwent surgical resection of ovarian cancer between 2012 and 2014. Forty-four normal ovarian tissues were collected from patients undergoing cervical cancer surgery. No local or systemic treatment was administered to these patients prior to the operation. All tissue samples were washed with sterile PBS before being snap-frozen in liquid nitrogen and stored at −80°C until analysis. The pathological parameters were evaluated by an experienced pathologist. Patient follow-up was performed every 3 months during the first post-surgical year and every 6 months thereafter until 1 January 2018. Disease-free survival (DFS) was calculated from the date of surgery to the date of recurrence or final follow-up as appropriate.
| Cell lines and culture conditions
Cells were obtained as follows: the HEK-293T and ES-2 cell lines were purchased from the Cell Bank of Type Culture Collection (CBTCC, Chinese Academy of Sciences, Shanghai, China). The RMG-1, TOV21G, OVCA420 and OVISE cell lines were purchased from Jingdu Biotech (Shanghai, China). All six cell lines were cultured in DMEM (HyClone). All media were supplemented with 10% foetal bovine serum (10% FBS, Gibco), 100 U/mL penicillin (Gibco) and 100 mg/mL streptomycin (Gibco), and all cell lines were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
| RNA isolation, reverse transcription and quantitative real-time PCR
As described in previous reports, total RNA was extracted from the tissue samples and cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Reverse transcription (RT) and quantitative real-time PCR (qRT-PCR) kits (Takara, Dalian, China) were utilized to evaluate the mRNA expression levels of the indicated genes. PCR primers were designed and synthesized using a primer design tool (Vector NTI; The primers used in this study are listed in Table S1 ). The relative quantification value for each target gene was expressed as 2 −ΔΔCT
. β-Actin was used as the internal reference for the mRNA expression, and U6 was used as the internal reference for miRNA expression.
| Plasmids, lentivirus construction, small interfering RNAs and cell transfections
Small nucleolar RNA host gene 6 was cloned into the expression Table S2 . miR-4465 mimics were purchased from Synbio Technologies (Suzhou, China). The experiments were repeated independently in triplicate.
| Cell proliferation assays
| Cell wound healing and invasion assays
| Western blotting
Cells were lysed in RIPA buffer (Sigma-Aldrich) supplemented with protease inhibitor (Roche, Basel, Switzerland) and phosphatase inhibitor (Roche). The protein concentration was measured using a BCA protein assay kit (Thermo Scientific, USA). Rabbit anti-EZH2, anti-MMP2, anti-MMP9, anti-N-Cadherin and anti-E-Cadherin primary antibodies were purchased from Cell Signaling Technology.
| In vivo experiments and immunohistochemical staining
Female BALB/c nude mice 6-8 weeks of age were purchased from the Shanghai Laboratory Animal Center at the Chinese Academy of Immunohistochemical staining was then performed. Specimens were incubated with anti-Ki-67 antibody (1:100; Servicebio, China) overnight at 4°C and were then incubated with a biotinylated secondary antibody (1:100, goat anti-rabbit/IgG) for 30 minutes at 37°C.
| Subcellular fractionation
Separation of the nuclear and cytosolic fractions of TOV21G and RMG-1 cells was performed with a PARIS kit (Life Technologies; Thermo Fisher Scientific, Inc), according to the manufacturer's protocol.
| Luciferase assay
The wild-type (WT) or mutant (MUT) SNHG6 binding sites were subcloned into the pGL3-Basic vector (Promega, Madison, WI). HEK-293T cells were seeded into 96-well plates. miR-4465 mimics or a negative control (NC) sequence (RiboBio, Guangzhou, China) were cotransfected with pGL3-SNHG6 or pGL3-SNHG6-MUT. Two days after transfection, cells were collected, and luciferase activity was determined using a Dual
Luciferase Reporter Assay System (Yeason, Shanghai, China). Similarly, the EZH2-3′UTR and EZH2-3′UTR-MUT plasmids containing the putative binding site of miR-4465 were constructed and cloned into a firefly luciferase expression vector (RiboBio). HEK-293T cells were seeded into 96-well plates and transfected with either pGL3-EZH2-3′UTR or pGL3-EZH2-3′UTR-MUT reporter vector, together with a miR-106b-5p mimic or NC using Lipofectamine 3000 (Invitrogen). After 48 hours, cells were harvested, and the firefly and Renilla luciferase activities were measured using the dual luciferase reporter assay system (Yeason).
| Statistical analysis
All statistical analyses were performed with spss 18.0 (IBM, SPSS, Chicago, IL). The significance of the differences between the groups was estimated using Student's t test, the chi-squared test or the Wilcoxon test as appropriate. The overall survival (OS) and DFS rates were calculated using the Kaplan-Meier method with the log-rank test for comparison. A value of P < 0.05 indicated a significant difference.
| RE SULTS
| SNHG6 is up-regulated in OCCC and is associated with poor prognosis
To explore the role of SNHG6 in OCCC, we first examined its expression in 48 patients with OCCC using qRT-PCR. The results showed higher SNHG6 expression in OCCC tissues than in normal ovarian tissues (P = 0.0139; Figure 1A ). In addition, clinicopathological correlation analysis was conducted, and the 48 OCCC patients were divided into the high-and low-expression groups based on the median expression value. As shown in Table 1 , high-SNHG6 expression was strongly associated with vascular invasion and distant metastasis, suggesting that SNHG6 may be involved in OCCC invasion and metastasis. The OS and progression-free survival (PFS) curves were then plotted according to the SNHG6 expression level using the Kaplan-Meier method. As shown in Figure 1B and 1, high-SNHG6 expression was significantly correlated with both shorter OS (P = 0.039) and shorter PFS (P = 0.032) times.
| SNHG6 promotes the proliferation of OCCC cells
Aiming to identify a function of SNHG6, we profiled its expression with that in the control groups ( Figure 2G ).
| SNHG6 enhances the invasion and migration of OCCC cells
To determine whether SNHG6 promotes OCCC cell invasion and migration, we performed Transwell and wound healing assays. Knockdown of SNHG6 resulted in a decrease in the number of invaded cells relative to the number of invaded control cells (P < 0.05; Figure 3A) ; conversely, SNHG6 induction increased the invasive ability of ES-2 and OVCA420 cells (P < 0.05; Figure 3B ). Moreover, the migration capacity was decreased when SNHG6 was down-regulated (P < 0.05; Figure 3C ). The migration assay results were verified by pcDNA3.1-SNHG6 transfection (P < 0.05; Figure 3D ). Accordingly, the Western blotting results showed that SNHG6 knockdown down-regulated the expression of invasion-promoting proteins such as N-cadherin, MMP2
and MMP9 and up-regulated the expression of the invasion-suppressing protein E-cadherin ( Figure 3E ). Collectively, these results suggest that SNHG6 may enhance OCCC cell migration and invasion.
| SNHG6 knockdown inhibits the growth of OCCC xenografts in vivo
To provide in vivo evidence for the oncogenic role of SNHG6 in OCCC,
we established cell lines with stable SNHG6 knockdown for use in a xenograft mouse model; the knockdown efficiency is shown in Figure 4A .
Ten mice were injected subcutaneously with TOV21G-NC and TOV21G-shRNA cells, and all developed detectable tumours ( Figure 4B ).
However, knockdown of SNHG6 markedly reduced the increase in the tumour volumes in the xenograft mouse model ( Figure 4C) . Additionally, the size and weight of SNHG6 knockdown tumours were lower than those of NC tumours ( Figure 4D and 4) . In addition, Ki-67 staining, which represents the proliferation index, was lower in the SNHG6 knockdown groups than in the control groups ( Figure 4F ). Therefore, SNHG6 may promote OCCC tumourigenesis both in vitro and in vivo. 
| SNHG6 functions as a sponge for miR-4465 in OCCC cells
| SNHG6 influences the expression of the miR-4465 target gene EZH2
To identify the targets of SNHG6 ceRNA, target prediction tools (TargetScan; http://www.targe tscan.org/vert_50) were used and a literature review was conducted to evaluate the potential miR-4465 target genes. Among these potential target genes, EZH2
was selected as the predicted target. Enhancer of zeste homolog 2 is also considered an important factor in EMT, which is associated with tumour growth and metastasis. We first examined whether Figure 6D ). In addition, EZH2 expression was decreased by miR-4465 mimics in TOV21G and RMG-1 cells ( Figure 6E ). These results suggest that SNHG6 promotes OCCC cell proliferation and invasion through reducing miR-4465 binding to EZH2 mRNA. . (A,B) The invasion potential of cells transfected with the SNHG6 small interfering RNAs (siRNAs) or the overexpression plasmid was assessed using a Transwell assay. The scale bar represents 50 μm. (C,D) The migration ability of cells with altered SNHG6 expression was evaluated using a wound healing assay; images of TOV21G, RMG-1, ES-2 and OVCA420 cells were captured at 0 and 48 h post wounding. The scale bar represents 200 μm. E, Western blot analysis was used to determine the N-cadherin, E-Cadherin, MMP2 and MMP9 expression levels. β-Actin or cytoplasmic 1 (ACTIN) was used as the reference. *P < 0.05, **P < 0.01, ***P < 0.001 vs negative control (NC) 
| SNHG6 facilitates tumour proliferation and metastasis via miR-4465
As we found that SNHG6 directly binds to miR-4465, we next investigated the coregulation of OCCC cell proliferation and metastasis by SNHG6 and miR-4465. The CCK-8 and colony formation assay results showed that the proliferation of TOV21G and RMG-1 cells was increased when SNHG6 expression was up-regulated and inhibited when miR-4465 was overexpressed; however, the promotive effect of the SNHG6 overexpression plasmid on OCCC cell growth was partially restored by transfection with miR-4465 mimics (P < 0.05; Figure 7A and 7) . In addition, the Transwell assay by cotransfection with miR-4465 mimics (P < 0.05; Figure 7C ).
Similarly, the SNHG6-induced promotion of migration was reversed by miR-4465 mimics (P < 0.05; Figure 7D ).
| D ISCUSS I ON
Recently, the vast majority of lncRNA transcripts have been discovered through high-throughput techniques. [23] [24] [25] However, although these techniques quantify these transcripts, only a few have been shown to be involved in regulating a diverse array of biological processes. 26 This study demonstrated the roles of SNHG6, whose functions in other cancers have been suggested in previous studies. [17] [18] [19] [20] For example, Chang et al reported that SNHG6 promotes tumour growth and metastasis by inducing EMT in hepatocellular carcinoma. 27 Guo et al showed the role of lncRNA SNHG6 in suppressing the production of the universal methyl donor SAMe and the impact of SAMe on global DNA methylation levels in liver cancer, also highlighting the potential benefit of SAMe for the treatment of liver cancer. 22 In addition, SNHG6 was found to be up-regulated in gastric cancer and to promote cell proliferation and EMT through epigenetically silencing p27 and sponging miR-101-3p. 20 Although the biological function of SNHG6 has been explored in some types of cancer, the detailed mechanism by which SNHG6 acts in OCCC [33] [34] [35] In our in vitro systems, ectopic expression of SNHG6 was sufficient to increase the expression of EZH2.
Moreover, we confirmed that SNHG6 promoted OCCC cell proliferation and metastasis, which was restored by miR-4465 mimics. These data suggest that SNHG6 exerts its pro-tumour effects at least in part by regulating miR-4465 expression.
In conclusion, this study is the first to investigate a potential mechanism of the SNHG6/miR-4465 axis in OCCC progression.
Increased expression levels of SNHG6 are associated with tumour progression and are inversely correlated with prognosis. In addition, SNHG6 functions as a ceRNA, regulating EZH2 expression by competitively binding miR-4465. These findings provide mechanistic insight into the role of SNHG6 in promoting OCCC metastasis and suggest that SNHG6 is an important prognostic factor and therapeutic target.
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